#Hidradenitis Suppurativa Market

[snarp]

May have just figured out why the lesions have been getting worse! I got the new bottle in early December.

TL;DR, sulfate-free cleansers tend to require more scrubbing for effective cleaning/rinsing. This isn't good for people with skin conditions that are aggravated by friction. Which is, practically-speaking, most people with skin conditions!

And since this cleanser is marketed towards people with "Itchy, Dry Skin" (major symptom of eczema), reviews since the formula change in November have been almost 100% negative. Most reviewers aren't sure why it's now irritating their skin, but they know that it is.

(Notably, in my case, hidradenitis suppurativa-affected hair follicles can easily become inflamed to the size of a thumbnail if the hair gets tugged on too hard. However, since HS also affects the skin's ability to fight off infection, failing to clean the area well enough is dangerous, too! Sulfate-free products are trying to kill me.)

[coherentmicom]

https://www.timessquarereporter.com/health/hidradenitis-suppurativa-treatment-market-to-register-high-growth-driven-by-increasing-disease-prevalence

[trendingrepots]

Adalimumab Market - Forecast(2024 - 2030)

Adalimumab Market Overview

Adalimumab Market Size is forecast to reach $3245.8 Million by 2030, at a CAGR of 6.20% during forecast period 2024-2030. Adalimumab is a monoclonal antibody and disease-modifying antirheumatic medication that acts by inactivating tumor necrosis factor-alpha. It is marketed under the brand names Humira and Exemptia, among others. The original adalimumab drug is sold under the brand name Humira. New versions of adalimumab are known as adalimumab biosimilars. Biosimilars are similar versions of original biological medicines. Adalimumab is a drug used to treat rheumatoid arthritis and ankylosing spondylitis which affects the musculoskeletal system, Crohn’s disease, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and other diseases. It was first introduced in the United States by Abbvie and was approved by the FDA in 2002. It is used to alleviate inflammation by acting on the immune system. The growing prevalence of arthritis and skin disorders, adoption of a sedentary lifestyle, and growing obese population are some of the factors driving the Adalimumab Market growth during the forecast period 2024-2030.

 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞

Report Coverage

The report: “Adalimumab Market Forecast (2024-2030)", by Industry ARC covers an in-depth analysis of the following segments of the Adalimumab Market.

By Disease- Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others. By Type- Adalimumab, Adalimumab Biosimilar. By End-Users- Hospitals, Specialty Clinics, and Others. By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

Geographically, North America held a dominant market share in the year 2021 on account of the increasing prevalence of psoriasis arthritis, highly informed people knowing the benefits of adalimumab, and high healthcare expenditure. Asia-Pacific is expected to offer lucrative growth opportunities to the manufacturers owing to increasing prevalence of Crohn's disease and ulcerative colitis., demand for better healthcare facilities as well a boost in the investments done by government and private companies in pharma industry. The proliferation of Rheumatoid arthritis is predicted to augment the market growth during the forecast period of 2022-2027.

The growing prevalence of arthritis and skin disorders is estimated to drive the market growth of the Adalimumab Market. High cost as well as lack side effects of adalimumab poses threat to the market growth.

A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Adalimumab Market Report.

[healthcareanna]

Biosimilars Market Size, Trends, Growth Analysis 2032

Biosimilars Market Overview

An integral component of the Biosimilars Market is the emergence of follow-on biologics. These biologics, which closely resemble existing biologic drugs, offer additional options for patients and healthcare providers. Follow-on biologics undergo rigorous testing to demonstrate similarity to the reference product, ensuring interchangeability and therapeutic equivalence. With their introduction, follow-on biologics stimulate competition in the biopharmaceutical industry, driving down prices and promoting innovation. As the demand for cost-effective biologic therapies continues to grow, the Biosimilars Market stands to benefit from the availability and acceptance of follow-on biologics, expanding treatment options and improving patient outcomes.

According to Market Research Future (MRFR), the biosimilars market insights was valued at USD 29.7 billion in 2023 and is projected to grow from USD 36.79 Billion in 2024 to USD 161.95 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.35% during the forecast period (2024 - 2032).

Biosimilars Market: Latest News and Developments

The FDA has approved the first Humira biosimilar. Adalimumab-bwwd (Cyltezo), a Humira biosimilar, received FDA approval in January 2023 for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Rising use of biosimilars in the treatment of cancer. A growing number of biosimilars are being used to treat cancer. The FDA authorised filgrastim-sndz (Zarxio), pegfilgrastim-jmdb (Onpro), and trastuzumab-dkst (Herzuma) as three biosimilars for the treatment of cancer in 2022.

Market Segmentation

Biosimilars industry can be considered with respect to product, applications, and end users.

The products based on which the market has been split into are recombinant glycosylated proteins, recombinant peptides, and recombinant non-glycosylated proteins. Recombinant non-glycosylated proteins are the biggest segment in the global market, thanks to the soaring cases of chronic disorders ranging from growth hormone deficiency to diabetes. As a result, recombinant non-glycosylated proteins are therapeutically used as they are readily available and are cost-effective.

Application-wise, the biosimilars market caters to chronic diseases, oncology, blood disorders, autoimmune diseases, infectious diseases, growth hormone deficiency, and more. Blood disorders have emerged as the top segment, as a result of the rising burden of the condition worldwide and the increased use of biosimilars by virtue of their low cost and the overall reduction in the treatment cost.

Major end users in the global market are hospitals and clinics as well as research institutes. Hospital and clinics are healthcare settings where treatment options and skilled professionals are easily available, and therefore, have emerged as the leading segment in the global industry.

Regional Status

Europe, MEA or Middle East & Africa along with the Americas, APAC or Asia Pacific are the primary markets for biosimilars.

Europe has taken the lead in the global market, as the region houses a vast elderly pool, with close to one fifth of the overall EU population aged more than 65 years. This has given way to several lifestyle-related disorders such as oncology, autoimmune diseases, diabetes, to name a few. Presumably, the scenario has raised the demand for biosimilars and can mean higher market growth over the next few years. In addition to this, numerous blockbuster biologics are on track to lose patent in the coming years, which should present lucrative opportunities to the biosimilar manufacturers.

The North American market displays a bright outlook and can emerge quite lucrative in the coming years, in view of the surging burden of chronic ailments in Canada and the United States. The rising spending on research activities by the healthcare agencies also fuels the market expansion in the region. Favorable reimbursement landscape in the region, especially in the US, encourages healthy competition as it results in lower incentives for the players to compete based on price.

The APAC market is slated to witness considerable growth, with China, South Korea and India offering a host of lucrative opportunities for drug development as well as commercialization. These are generics-driven countries and are known for frequently launching new and advanced manufacturing platforms, which has brought down the costs associated with biosimilar production. In the coming few years, majority of the patent expiries is touted to be in biosimilars, which is deemed as a profitable aspect by leading manufacturers and can translate into substantial market growth.

Eminent Vendors

Top global key players listed by biosimilars market outlook report include Stada Arzneimittel AG (Germany), Teva Pharmaceuticals (Israel), Biocon (India), Pfizer (US), Sandoz International (Germany), Eli Lily & Company (US), Actavis, Inc. (US), Dr. Reddy’s Laboratories (India), Cipla Ltd (India), Amgen, Inc. (US), Samsung Biologics (South Korea), Hospira Inc.(US), Mylan, Inc.(US), Celltrion (South Korea), to mention a few.

More Related Trending Topics

Medical Foods market

Insomnia market

Blockchain Technology in Healthcare market

Drug Device Combination market

Prefilled Syringes market

[columbianewsupdates]

Hidradenitis Suppurativa Market Projected to Expand at a 13.5% CAGR, According to DelveInsight | HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), and others.

http://dlvr.it/T6jqXy

[alicesara611]

Forecasting Success: Examining the Humira Market's Trajectory Over By 2023 to 2030

The global humira market is expected to reach US$ 3871.4 million by 2030, at a CAGR of 25.9%. The market is driven by the increasing prevalence of inflammatory diseases, the aging population, and the rising demand for biologics, driven by factors such as an aging population, rising prevalence of chronic inflammatory diseases, and advancements in medical technology. However, the introduction of biosimilars, which are highly similar to Humira in terms of structure and function, is expected to disrupt the market dynamics.

In the realm of pharmaceuticals, Humira, a tumor necrosis factor (TNF) blocker, stands as a towering figure, having revolutionized the treatment of inflammatory conditions. Its efficacy and broad spectrum of applications have propelled it to the forefront of the healthcare industry, generating substantial revenue and garnering significant attention. However, as Humira's patent protection wanes, the market landscape is poised for a significant transformation, with the emergence of biosimilars and the potential for increased competition.

Get your Sample Report with Latest Market Information! https://absolutemarketresearch.com/Global-Humira-Market/1269/request-sample

The Humira market is poised for a period of significant change and evolution in the coming years. The emergence of biosimilars will undoubtedly reshape the market landscape, introducing new players and intensifying competition. While Humira is expected to maintain a strong position in the market, biosimilars are poised to capture a growing share, offering patients with more affordable treatment options. The Humira market will undoubtedly remain dynamic and evolving, presenting both challenges and opportunities for industry players.

Humira Market: Key Takeaways:

The global Humira market is expected to reach US$ 3871.4 million by 2030, growing at a CAGR of 25.9%.

The increasing prevalence of inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, is driving the growth of the Humira market.

The rising adoption of biosimilars is expected to put pressure on Humira's prices, but it is also expected to expand the market by making Humira more accessible to patients in developing countries.

The Asia-Pacific region is expected to be the fastest-growing market for Humira, driven by the increasing prevalence of inflammatory diseases and the growing adoption of biosimilars.

Humira Market Regional Outlook:

North America is the largest market for Humira, accounting for over 60% of the global market share in 2023.

Europe is the second-largest market for Humira, accounting for over 30% of the global market share in 2023.

The Asia-Pacific region is the fastest-growing market for Humira, due to the increasing prevalence of inflammatory diseases and the growing adoption of biosimilars.

Humira Market Key Players:

AbbVie

Amgen

Boehringer Ingelheim

Cadila Healthcare

Eisai

Torrent Pharmaceuticals

Humira Market Segmentation:

By Indication:

Rheumatoid Arthritis

Psoriatic Arthritis

Crohn's Disease

Ulcerative Colitis

Ankylosing Spondylitis

Hidradenitis Suppurativa

Juvenile Idiopathic Arthritis

By Type:

Humira Syringe

Humira Pen

By Dosage Strength:

40mg/0.4mlg

80mg/0.8mlg

20mg/0.2mlg

10mg/0.1mlg

By Drug Type:

Branded

Generics

By Route of Administration:

Parenteral

Oral

By Population Type:

Adults

Children

By End User:

Hospital/Clinical Laboratories

Physician Offices

Reference Laboratories

Other End Users

By Distribution Channel:

Direct Tender

Pharmacy

E-commerce

[rohans18]

Hidradenitis Suppurativa Market

[coherentmicom]

https://www.timessquarereporter.com/health/hidradenitis-suppurativa-treatment-market-to-register-high-growth-driven-by-increasing-disease-prevalence

[expertmarketresearchreport]

Hidradenitis Suppurativa Treatment Market Report 2023-2028

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and sinus tracts in the areas of the body with apocrine glands, such as the armpits, groin, and buttocks. Read More: Hidradenitis Suppurativa Treatment Market Report

[mediwinpharma]

Top Demand Drug companies in India in the Last Decade

Over the past decade, the demand for drug companies in India has significantly increased, reflecting the country's evolving healthcare industry. In fact, a report by Statista indicates that the Indian healthcare and pharmaceuticals sector is anticipated to experience an extraordinary growth rate of 754% between 2017 and 2060.

As India emerges as a major player in the pharmaceutical industry, it is critical to understand the demand for various drugs in the country. It provides valuable insights into the health concerns of the people, the shifting demographics, and the evolving medical requirements.

So, read the article below to gain in-depth knowledge about high-demand drugs in India and the factors influencing this demand. This knowledge can help drug companies to focus their R&D and production to cater to the specific needs of the Indian market.

Top 8 Demand Drugs in India

Some of the best drugs in India and their uses are given below:

1. Humira

Humira (adalimumab) is a widely used biological medication known for its effectiveness in treating various conditions. It functions as a tumor necrosis blocker, which helps suppress the immune system by blocking the activity of factor-α (TNF). TNF is a protein associated with inflammation and autoimmune diseases.

Uses

Treats rheumatoid arthritis in adults.

Indicated for adults with hidradenitis suppurativa (HS).

Tackles chronic plaque psoriasis.

Treats non-infectious intermediate, posterior, and panuveitis.

Approved for adult patients with active ulcerative colitis.

Used to reduce signs and symptoms of active ankylosing spondylitis.

2. Keytruda

Keytruda is a cancer medication that contains the active substance pembrolizumab. It belongs to a class of drugs known as immune checkpoint inhibitors. Keytruda blocks a protein called PD-1 in immune cells. This allows the immune system to recognize and attack cancer cells.

Uses

Treats advanced or metastatic melanoma.

Treats advanced NSCLC.

Treats children with classical Hodgkin lymphoma.

Treats advanced renal cell carcinoma.

Used in combination with chemotherapy or other cancer medicines to treat oesophageal cancer.

Prevents blood clots in cases like broken bones, immobility, surgeries, etc.

3. Eliquis

Eliquis is a prescription medication that belongs to the class of drugs known as anticoagulants or blood thinners. It is considered an anticoagulant because apixaban is its active ingredient. Eliquis is FDA-approved for treating and preventing dangerous blood clots that can block blood vessels in the body.

Uses

Treats deep vein thrombosis (DVT).

Prevents stroke.

Treats pulmonary embolism (PE).

Reduces the risk of systemic embolism.

Avoids thromboembolic events in individuals with chronic kidney disease.

Used as an anticoagulant therapy during cardiac catheterization procedures

4. Revlimid

Revlimid is a medication that contains the drug lenalidomide. It is a thalidomide analog, an immunomodulatory drug (IMiD) with various putative molecular targets and biological effects. Revlimid is primarily used to treat multiple types of cancers affecting blood cells.

Uses

Used in combination with dexamethasone for the treatment of multiple myeloma.

Used as maintenance therapy after an autologous hematopoietic stem cell transplant (auto-HSCT).

Treats lymphoplasmacytic lymphoma.

Used off-label for the treatment of systemic light-chain amyloidosis.

Tackles myelodysplastic syndromes.

Used in combination with rituximab to treat follicular and marginal zone lymphoma.

5. Imbruvica

Imbruvica is a medication available in tablet and capsule forms that are taken orally once a day. Its active ingredient is ibrutinib. Ibrutinib works by inhibiting specific proteins in cancer cells, slowing their growth, and preventing the spread of cancer.

Uses

Treats mantel cell lymphoma (MCL).

Treats chronic lymphocytic leukemia (CLL).

Tackles small lymphocytic lymphoma (SLL).

Treats waldenström's macroglobulinemia (WM).

Manages chronic graft versus host disease (cGVHD).

Prescribed off-label to diffuse large B-cell lymphoma (DLBCL).

6. Stelara

Stelara is a highly effective medication that contains ustekinumab. Ustekinumab is a monoclonal antibody derived from immune system cells. It is specifically designed to target and alleviate the symptoms of various inflammatory conditions associated with immune system dysfunction.

Uses

Provides relief for people suffering from this autoimmune skin condition.

Treats psoriatic arthritis for adults.

Deals with the challenges of moderate to severe Crohn's disease.

Treats adults with this type of inflammatory bowel disease.

Used off-label in the treatment of active systemic lupus erythematosus.

Used for investigational purposes of hidradenitis suppurativa.

7. Xarelto

Xarelto (rivaroxaban) is a medication also classified as a blood thinner. It works by inhibiting the activity of Factor Xa, an enzyme involved in blood clot formation. While Xarelto does not thin the blood, it helps prevent the formation of blood clots and reduces the risk of strokes and systemic embolisms in certain medical conditions.

Uses

Reduces the risk of stroke and systemic embolism with nonvalvular atrial fibrillation.

Treats and maintains drugs for deep vein thrombosis (DVT).

Reduces the risk of recurrence of pulmonary embolism.

Prevents blood clot formation in patients suffering from heart failure, respiratory disease, or infectious diseases.

Used as a prophylactic treatment to prevent blood clots in patients with cancer.

Prevents the recurrence of ischemic events, such as heart attacks or peripheral artery disease

8. Opdivo

Opdivo is an immunotherapy drug that belongs to a class of medications known as checkpoint inhibitors. It targets the PD-1 receptor, found on the surface of T cells, the immune cells responsible for fighting cancer. PD-1 helps regulate immune responses in healthy tissues, but cancer cells can exploit this mechanism to evade immune attacks. Opdivo blocks the interaction between PD-1 and PD-L1/PD-L2 molecules in cancer cells. This blockage enables T cells to recognize and destroy cancer cells effectively.

Uses

Treats advanced melanoma.

Treats non-small cell lung cancer.

Used in combination with ipilimumab for newly diagnosed malignant pleural mesothelioma.

Treats adult patients with classical Hodgkin lymphoma.

Treats patients with recurrent or metastatic head and neck squamous cell carcinoma.

Treats with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colon.

Factors that Impact the Demand for the Drugs

Here are four key factors that impact the demand for drugs:

1. Disease Prevalence and Epidemiology

The prevalence of diseases and their impact on the population greatly influence the demand for drugs. The burden of chronic diseases, or infectious outbreaks, shapes the market for specific medications to treat and manage these conditions.

2. Demographic Changes

Changing demographics, such as aging populations and urbanization, play a crucial role in drug demand. Different age groups have varying healthcare needs, and understanding demographic shifts helps target drug development and delivery strategies accordingly.

3. Economic Factors

Economic factors, including income levels, affordability, and healthcare expenditures, substantially impact drug demand. If medicines are expensive or not affordable, people may struggle to access their prescribed treatments. The cost and accessibility of medications greatly affect the choices people make and their ability to follow through with the necessary treatments.

4. Government Policies and Regulations

Regulatory frameworks, pricing regulations, reimbursement policies, and intellectual property rights all affect the availability, accessibility, and affordability of medicines. This further influences its demand in the market. Understanding and navigating these factors is crucial for ensuring that drugs are accessible and affordable to those who need them.

The Bottom Line

In conclusion, understanding the demand for drugs in India is vital for pharmaceutical companies, policymakers, and healthcare providers. By now, you must be aware of the factors that significantly impact drug demand. By aligning their strategies with these factors, stakeholders can meet the evolving healthcare needs of the Indian market effectively.

Moreover, if you're looking for a trusted name in the pharmaceutical industry for reliable and high-quality medications, consider Mediwin Pharmaceuticals. They have been one of the top pharma companies serving India since 1990. It is among the top pharmaceutical manufacturing companies in Ahmedabad because they facilitate effective medications for chronic conditions, specialized therapies, and preventive care.

So, visit Mediwin’s website today to discover its diverse product portfolio!

Source link